中医药治疗骨髓炎进展

骨髓炎是骨科的常见病之一,中医称之为＂附骨痈、附骨疽＂急性骨髓炎预后较好,但若迁延为慢性骨髓炎则病情缠绵难愈。中医治疗该病有着悠久的历史,且取得良好的效果,现在将近年来对该病的治疗情况作一简要总结。     

中西医药物治疗失眠概述

失眠是一种常见、多发的病症,其发病率逐年升高,已日趋成为提高国民生存质量的首要问题,受到社会各界的重视。目前治疗失眠的方法多种多样,但目前最常用的治疗失眠的方法仍然是药物治疗,文章主要对中西医药物治疗失眠进行了综述。     

不明原因慢性咳嗽中医临床研究近况

不明原因慢性咳嗽是临床常见疾病,也是近年来中西医研究的热点。现主要就病因病机、治则治法、遣方用药等方面,综述近年来中医在这方面的研究概况。认为中医药在不明原因慢性咳嗽的治疗方面取得了较好的效果,部分学者在辨证论治的基础上结合西医学的不同病因进行辨证与辨病相结合治疗,是本病近年来中医治疗学上的一大特点,并提出一些展望。     

近年来针刺治疗Bell麻痹探析

通过对近年来针刺为主治疗Bell麻痹的综述,进一步明确了针刺治疗该病在医学界的地位,但至今却没有被大家普遍认同的针刺综合治疗方案,希望借此引起同行的重视,并能以点带面,推动针灸学的国际化发展。     

中医药对呼吸道合胞病毒感染Thl/Th2漂移影响的研究进展

对近几年来呼吸道合胞病毒(respiratory syncytial virus,RSV)感染状态下Thl/Th2漂移状态以及中医药对RSV感染Thl/Th2漂移状态影响的研究进展进行综述,为以后相关研究进行展望。认为应深入探讨免疫病理损伤在RSV感染过程中的发生及变化规律及中药对其的影响,从而探索中药疗效的新机制,指导RSV感染的临床治疗。     

流行性感冒中医药治疗研究

收集建国60年来的流感相关资料,从病因、病机、临床治疗等方面,对中医药防治流感进行了较全面的概述。病因内外相关,病机多角度认识,注意到气候变化以及运气的影响。治法上多法联用,病证结合,截断治疗等,体现了对流感治疗研究的不断深化。提出今后应加强古今文献的系统研究、流感专病与提取证候要素结合组方规律的研究、以及重症病例的防治研究等,方法强调需加强临床对照研究,以适应流感防治的需求更好的发挥中医药优势。     

舒张性心力衰竭的中西医诊疗进展

舒张性心力衰竭是一种心室主动松弛能力受损及被动顺应性下降所致的独立临床症候群。近20年流行病学显示DHF占所有HF患者的50%以上,且预后凶险程度与SHF相同。目前已引起相当的重视,老年、女性、糖尿病、肥胖、高血压和左室肥厚都是DHF的常见病因。早期检出和积极防治DHF有可能减少晚期混合性心力衰竭的发病率。然而目前尚没有统一明确的有关DHF的诊断和治疗标准,将简明叙述舒张性心力衰竭的概念及发病机制,从现代医学及传统医学2个方面阐述了舒张性心力衰竭的临床诊断和治疗的进展。     

陈以国教授治疗雷诺病临证经验简

雷诺病在中医学中属痹证范畴。目前临床未有雷诺病的特效药,且西药具有一定的副作用。陈以国教授在临床上,以＂舒阳郁、调气血＂为原则,选用四逆散加味治疗,具有良好的疗效。     

The PARTNER 3 Bicuspid Registry for Transcatheter Aortic Valve Replacement in Low-Surgical-Risk Patients

ObjectivesThe study compared 1-year outcomes between transcatheter aortic valve replacement (TAVR) patients with bicuspid aortic valve (BAV) morphology and clinically similar patients having tricuspid aortic valve (TAV) morphology.BackgroundThere are limited prospective data on TAVR using the SAPIEN 3 device in low-surgical-risk patients with severe, symptomatic aortic stenosis and bicuspid anatomy.MethodsLow-risk, severe aortic stenosis patients with BAV were candidates for the PARTNER 3 (Placement of Aortic Transcatheter Valves 3) (P3) bicuspid registry or the P3 bicuspid continued access protocol. Patients treated in these registries were pooled and propensity score matched to TAV patients from the P3 randomized TAVR trial. Outcomes were compared between groups. The primary endpoint was the 1-year composite rate of death, stroke, and cardiovascular rehospitalization.ResultsOf 320 total submitted BAV patients, 169 (53%) were treated, and most were Sievers type 1. The remaining 151 patients were excluded caused by anatomic or clinical criteria. Propensity score matching with the P3 TAVR cohort (496 patients) yielded 148 pairs. There were no differences in baseline clinical characteristics; however, BAV patients had larger annuli and they experienced longer procedure duration. There was no difference in the primary endpoint between BAV and TAV (10.9% vs 10.2%; P = 0.80) or in the rates of the individual components (death: 0.7% vs 1.4%; P = 0.58; stroke: 2.1% vs 2.0%; P = 0.99; cardiovascular rehospitalization: 9.6% vs 9.5%; P = 0.96).ConclusionsAmong highly select bicuspid aortic stenosis low-surgical-risk patients without extensive raphe or subannular calcification, TAVR with the SAPIEN 3 valve demonstrated similar outcomes to a matched cohort of patients with tricuspid aortic stenosis.